Clinical trials: PET Imaging in Patients With Prostate Cancer
Prostate Cancer
Comparison of PSMA-based 18F-DCFPyL PET/CT to Conventional Imaging in the Evaluation of Patients With Castration-Resistant Prostate Cancer
We intend to validate 18F-DCFPyL for imaging patients with metastatic, castrate-resistant PCa (CRPC), so that it may be used to full advantage in supporting existing and emerging therapies for a spectrum of patients suffering…
- Trial name
- NCT02856100
- Testing
- 18F DCFPyL- Radiopharmaceutical
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8
Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial
This phase II trial studies how well a short course of androgen deprivation therapy (ADT) with relugolix works in increasing expression of prostate-specific membrane antigen (PSMA) and improving diagnostic imaging with PSMA…
- Conditions
- Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
- Trial name
- NCT07025369
- Testing
- Biospecimen Collection, Computed Tomography, Flotufolastat F-18 Gallium
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Prostate Cancer
Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Patients With Prostate Cancer.
A multicenter, open-label, prospective Phase III clinical trial to evaluate INR101 injection for PET/CT imaging in patients with Prostate Cancer
- Trial name
- NCT06922903
- Testing
- INR101
- Where
- 32 sites in China
- Volunteers
- 240 people
- Sponsor
- Yunhe Pharmaceutical (Tianjin) Co., Ltd
Prostate Adenocarcinoma, Stage IIB Prostate Cancer
Copper Cu 64 TP3805 PET in Detecting Cancer in Patients With Prostate Cancer Undergoing Surgery
This pilot phase I trial studies copper Cu 64 TP3805 (Cu-64-TP3805) positron emission tomography (PET)/computed tomography (CT) in detecting cancer in patients with prostate cancer undergoing surgery to remove the entire prostate…
- Conditions
- Prostate Adenocarcinoma, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT02603965
- Testing
- Copper Cu 64 TP3805, Positron Emission Tomography, Computed Tomography
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma
Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer
This pilot clinical trial studies how well gallium Ga 68-DOTATATE positron emission tomography (PET)/computed tomography (CT) works in treating patients with castration resistant prostate cancer that has spread to other placed in…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v7
- Trial name
- NCT03448458
- Testing
- CT (Computed Tomography), Gallium Ga 68-DOTATATE, Positron Emission Tomography
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Emory University
Prostate Cancer
Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer
The advent of PSMA-PET has improved sensitivity and specificity in staging prostate cancer, particularly in intermediate- and high-risk disease.
- Trial name
- NCT07237269
- Testing
- Androgen Deprivation Therapy (ADT), Abiraterone, Prednisone
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- University of Nebraska
Prostate Cancer
PSMA-PET Imaging in Patients With Metastatic Prostate Cancer: Institutional Evaluation of Detection Yield Performance and Reproducibility
A promising imaging technique involving new prostate specific membrane antigen (PSMA) positron emission tomography (PET) tracers is emerging in metastatic prostate cancer (PCa).
- Trial name
- NCT03486886
- Testing
- PSMA -PET/CT scanning
- Where
- Canada
- Volunteers
- 29 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Prostate Cancer
Neoadjuvant PSMA-RLT in Oligometastatic PCa
Prospective single-center phase II study to evaluate the PSA, imaging and pathological response, as well as oncological outcomes of systemic radioligand therapy [177Lu]Lu-PSMAI\&T (PSMA-RLT) in patients planned for radical…
- Trial name
- NCT06259123
- Testing
- [177Lu]Lu-PSMA I&T
- Where
- Austria
- Volunteers
- 10 people
- Sponsor
- Medical University of Vienna
Thyroid Gland Carcinoma
Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients With Thyroid Cancer
This pilot clinical trial studies how well Gallium-68 prostate specific membrane antigen positron emission tomography (PET) work in diagnosing patients with thyroid cancer.
- Trial name
- NCT03463889
- Testing
- Gallium Ga 68-labeled PSMA-11, Magnetic Resonance Imaging, Positron Emission Tomography (PET)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of California, San Francisco
Prostate Cancer
Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Guided Biopsy in Men With Elevated PSA
In 22% of patients with elevated Prostate-specific antigen (PSA) MRI guided biopsy will not detect significant prostate cancer (PCA) (defined as either: Gleason score (GS) ≥ 3+4 or tertiary pattern 5, or final stage ≥ pT3a and/or…
- Trial name
- NCT03187990
- Testing
- [68Ga]PSMA-11, [18F]PSMA-1007
- Where
- Switzerland
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Irene Burger
Prostate Adenocarcinoma, PSA Level Greater Than 0.2
F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer
This study provides fluorine F 18 DCFPyL positron emission tomography/computed tomography (PET/CT) to participants with prostate cancer that has come back.
- Conditions
- Prostate Adenocarcinoma, PSA Level Greater Than 0.2, PSA Level Greater Than or Equal to Two, PSA Progression
- Trial name
- NCT03501940
- Testing
- Computed Tomography, Fluorine F 18 DCFPyL, Laboratory Biomarker Analysis
- Where
- United States
- Sponsor
- Andrei Iagaru
Prostate Carcinoma
68Ga-DOTA-Bombesin PET/MRI in Imaging Patients With Prostate Cancer
This clinical trial studies the use of gallium-68 (68Ga)-DOTA-Bombesin as the imaging agent for positron emission tomography (PET)/magnetic resonance imaging (MRI), collectively PET-MRI, in patients with prostate cancer.
- Trial name
- NCT02440308
- Testing
- 68Ga-DOTA-Bombesin, Magnetic Resonance Imaging (MRI) scan, Positron Emission Tomography (PET) scan
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Stanford University
Biochemically Recurrent Prostate Cancer
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies
Researchers are looking for a better way to treat men at high-risk of biochemical recurrence (BCR) of prostate cancer. BCR means that in men who had prostate cancer and were treated by either surgery and/ or radiation therapy…
- Trial name
- ARASTEP (NCT05794906)
- Testing
- Darolutamide (BAY1841788, Nubeqa), ADT
- Where
- 226 sites in United States, Australia and 21 more
- Volunteers
- 985 people
- Sponsor
- Bayer
Prostate Cancer
68Ga-RM2 Compared to 68Ga-PSMA-617 PET/CT for Prostate Cancer Imaging According to Various Metastatic Risks
Patients with primary prostate cancer (low, intermediate or high metastatic risk) for whom radical prostatectomy is indicated, will be invited to participate to the present study.
- Trial name
- UROPET (NCT03604757)
- Testing
- 68Ga-PSMA-617 PET/CT, 68Ga-RM2 PET/CT
- Where
- France
- Volunteers
- 22 people
- Sponsor
- University Hospital, Bordeaux
Breast Cancer, Head and Neck Cancer
The Biodistribution and Potential Diagnostic Ability of 18F FACBC in Patients With Head and Neck, Breast, and Prostate Cancer
See where the dye-like material (FACBC) goes in your body and how long it stays in your body. See how much of the dye-like material is picked up by your tumor Compare the FACBC pictures with other pictures (such as FDG PET scan)…
- Conditions
- Breast Cancer, Head and Neck Cancer, Prostate Cancer
- Trial name
- NCT00605488
- Testing
- novel PET tracer FACBC
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Healthy Male Subjects, Suspected Prostate Cancer
A Study of PET/CT Imaging Using INR101 Injection in Healthy Male Subjects and Patients With Suspected Prostate Cancer
Phase I/II study in the management of Healthy Male Subjects and patients with suspected prostate cancer.
- Trial name
- NCT06472531
- Testing
- INR101
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Yunhe Pharmaceutical (Tianjin) Co., Ltd
Recurrent Prostate Carcinoma
Gallium Ga 68-labeled PSMA-11 PET/CT and Fluciclovine F18 PET/CT in Imaging Participants With Recurrent Prostate Cancer After Surgery
This phase II trial compares how well gallium 68-labeled PSMA-11 positron emission tomography/computed tomography (PET/CT) works compared to fluciclovine F18 PET/CT in imaging participants with prostate cancer after surgery that…
- Trial name
- PSMA vs AXUMIN (NCT03515577)
- Testing
- Computed Tomography, Fluciclovine F18, Gallium Ga 68-labeled PSMA-11
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Jonsson Comprehensive Cancer Center
High Risk Prostate Carcinoma
[18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer
This is a multi-center, open-label, single arm Phase III clinical trial for the diagnostic efficacy assessment and safety evaluation by [18F]Florastamin PET/CT imaging examination to determine the presence of recurrent or…
- Trial name
- NCT05936658
- Testing
- [F-18]Florastamin
- Where
- 6 sites in South Korea
- Volunteers
- 138 people
- Sponsor
- FutureChem
Prostate Cancer
Phase I Clinical Study of HRS-9815 for PET/CT Imaging in Patients With Prostate Cancer
The study is being conducted to evaluate the the safety, pharmacokinetics, radiation dosimetry of HRS-9815 for PET/CT imaging in adult patients with prostate cancer.
- Trial name
- NCT06062355
- Testing
- HRS-9815 injection
- Volunteers
- 9 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Anal Carcinoma, Bladder Carcinoma
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
This phase I trial is evaluating a new imaging tracer (68Ga-FAPi-46) with positron emission tomography (PET)/computed tomography (CT) to determine where and to which degree the tracer (68Ga-FAPi-46) accumulates in normal and…
- Conditions
- Anal Carcinoma, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma
- Trial name
- NCT07118176
- Testing
- Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 FAPi-46
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Jonsson Comprehensive Cancer Center